摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-苯基-3-吡咯烷基丙-1-酮盐酸盐 | 833-86-3

中文名称
1-苯基-3-吡咯烷基丙-1-酮盐酸盐
中文别名
——
英文名称
1-(phenyl)-3-(1'-pyrrolidin)propanone hydrochloride
英文别名
1-phenyl-3-pyrrolidino-propan-1-one; hydrochloride;1-Phenyl-3-pyrrolidino-propan-1-on; Hydrochlorid;3-(1-pyrrolidinyl)propiophenone hydrochloride;3-pyrrolidinopropiophenone hydrochloride;β-(1-pyrrolidinyl)propiophenone hydrochloride;hydron;1-phenyl-3-pyrrolidin-1-ylpropan-1-one;chloride
1-苯基-3-吡咯烷基丙-1-酮盐酸盐化学式
CAS
833-86-3
化学式
C13H17NO*ClH
mdl
——
分子量
239.745
InChiKey
AACQWMDCFMYTSE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    溶于水

计算性质

  • 辛醇/水分配系数(LogP):
    2.78
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    20.3
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • WGK Germany:
    3

SDS

SDS:064a5300c9e6901acb20834f841512f3
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes
    作者:Kaan Kucukoglu、Halise Inci Gul、Parham Taslimi、Ilhami Gulcin、Claudiu T. Supuran
    DOI:10.1016/j.bioorg.2019.02.008
    日期:2019.5
    their inhibitory activity against hCA I, hCA II, and AChE enzymes. All compounds in N, P, and R-series inhibited hCAs (I and II) and AChE more efficiently than the reference compounds acetazolamide (AZA), and tacrine. According to the activity results, the most effective inhibitory compounds were in R-series with the Ki values of 203 ± 55-473 ± 67 nM and 200 ± 34-419 ± 94 nM on hCA I, and hCA II, respectively
    最近,抑制碳酸酐酶(hCA)和乙酰胆碱酯酶(AChE)作为药物干预多种疾病(如青光眼,癫痫,肥胖,癌症和阿尔茨海默氏病)的一种有希望的方法。牢记这一点,合成了N,N'-双[((1-芳基-3-杂芳基)亚丙基]肼二盐酸盐N1-N11,P1,P4-P8和R1-R6,以研究其对hCA的抑制活性I,hCA II和AChE酶。N,P和R系列中的所有化合物均比参考化合物乙酰唑胺(AZA)和他克林更有效地抑制hCA(I和II)和AChE。根据活性结果,对hCA I和hCA II而言,最有效的抑制化合物为R系列,Ki值分别为203±55-473±67 nM和200±34-419±94 nM。N,N' -N系列中的双[1-(4-氟苯基)-3-(吗啉-4-基)亚丙基]肼二盐酸盐N8,N,N'-双[1-(4-羟基苯基)-3-( P系列的哌啶-1-基)亚丙基]肼二盐酸盐和N,N'-双[1-(4-氯苯基)-3-(吡咯烷-1-基]亚丙基]肼二盐酸盐R5,
  • 3-phenyl-2-propeneamine derivatives, their preparation and compositions
    申请人:Rhone-Poulenc Sante
    公开号:US04686309A1
    公开(公告)日:1987-08-11
    The invention provides compounds of formula: ##STR1## in which R=H, halogen, alkyl, alkyloxy, alkythio, NH.sub.2, alkylamino, dialkylamino or CF.sub.3, R.sub.3 =H or alkyl, either R.sub.4 and R.sub.5 =H and R.sub.1 and R.sub.2 =H or alkyl, optionally substituted by alkenyl (2 to 4 C) or alternatively R.sub.1 and R.sub.2 form together a saturated heterocyclic ring containing 4 to 7 ring members and optionally containing another heteroatom such as O, S or N optionally substituted by alkyl, or R.sub.4 =H, R.sub.1 =H or alkyl and R.sub.2 and R.sub.5 together form an alkylene (3 to 4 C) radical and (i) either A=alkyl or phenyl which is unsubstituted or substituted by one or two substituents chosen from halogen, alkyl, alkyloxy, alkylthio, NH.sub.2, alkylamino, dialkylamino, NO.sub.2 or CF.sub.3 or alternatively A=pyridyl, benzyl or cycloalkyl (3 to 6C), Y=S, SO or SO.sub.2 or a radical: ##STR2## in which R.sub.6 =H or alkyl and R.sub.7 =H or alkylcarbonyl, alkyloxycarbonyl, alkylaminocarbonyl or benzoyl, optionally substituted by one or two halogen, alkyl, alkyloxy, alkylthio, NH.sub.2, alkylamino, dialkylamino, NO.sub.2 or CF.sub.3 groups, (ii) or Y and A together form a 1-hydroxycycloalkyl radical, the ring of which contains 5 or 6 C, optionally joined to a benzene ring, it being understood that the alkyl radicals and alkyl parts contain 1 to 4 C as a straight or branched chain, and that the invention relates to all the possible geometric and optical isomers as well as their mixtures. These compounds are useful as antidepressants.
    本发明提供式(I)化合物: ##STR1## 其中R=H、卤素、烷基、烷氧基、烷硫基、NH2、烷基氨基、二烷基氨基或CF3,R3=H或烷基,R4和R5=H且R1和R2=H或烷基,任选被2至4个碳的烯基取代;或者R1和R2一起形成含有4至7个环成员的饱和杂环环,任选含有另一个杂原子如O、S或N,任选被烷基取代;或者R4=H,R1=H或烷基,R2和R5一起形成3至4个碳的亚烷基基团;(i)A=烷基或苯基,未被取代或被一个或两个选自卤素、烷基、烷氧基、烷硫基、NH2、烷基氨基、二烷基氨基、NO2或CF3的取代基取代;或者A=吡啶基、苄基或3至6个碳的环烷基;Y=S、SO或SO2或基团: ##STR2## 其中R6=H或烷基,R7=H或烷基羰基、烷氧基羰基、烷基氨基羰基或苯甲酰基,任选被一个或两个卤素、烷基、烷氧基、烷硫基、NH2、烷基氨基、二烷基氨基、NO2或CF3基团取代;(ii)或者Y和A一起形成1-羟基环烷基基团,其环含有5或6个碳,任选与苯环稠合;其中烷基基团和烷基部分含有1至4个碳,可以是直链或支链;本发明涉及所有可能的几何异构体和光学异构体以及它们的混合物。这些化合物作为抗抑郁药有用。
  • Dramatically Accelerated Synthesis of β-Aminoketones via Aqueous Mannich Reaction under Combined Microwave and Ultrasound Irradiation
    作者:Gonghua Song、Yanqing Peng、Ruiling Dou、Jun Jiang
    DOI:10.1055/s-2005-872246
    日期:——
    An efficient green chemistry approach to the synthesis of β-aminoketones was developed under combined microwave and ultrasound irradiation. With this technique, the title compounds were rapidly synthesized in aqueous media with good yields.
    在微波和超声波联合辐照下,一种高效的绿色化学方法被开发用于合成β-氨基酮。利用这项技术,目标化合物在水介质中迅速合成,并获得了良好的产率。
  • Cytotoxicities of novel hydrazone compounds with pyrrolidine moiety: inhibition of mitochondrial respiration may be a possible mechanism of action for the cytotoxicity of new hydrazones
    作者:Kaan Kucukoglu、Mustafa Gul、Halise Inci Gul、Rengul Cetin-Atalay、Bernard Geny
    DOI:10.1007/s00044-018-2220-y
    日期:2018.9
    panone hydrochlorides with 1 mol of hydrazine hydrate and reported for the first time with their detailed spectral analysis and cytotoxicities towards human hepatoma (Huh7) and breast cancer (T47D) cell lines. Compounds R2, R6, and R7 with the IC50 values of 5.16, 6.96, and 5.96 μM, respectively, showed higher cytotoxic potency than the reference compound 5-FU with 7.0 μM against Huh7 cell line. However
    N,N'-双[1-芳基-3-吡咯烷-1-基]亚丙基]肼二盐酸盐(R1-R7)是由2摩尔1-芳基-3-(吡咯烷-1-基)反应合成的含1摩尔水合肼的-1-丙酮盐酸盐,并首次进行了详细的光谱分析和对人肝癌(Huh7)和乳腺癌(T47D)细胞系的细胞毒性报道。化合物R2,R6和R7的IC 50值分别为5.16、6.96和5.96μM,比具有7.0μM的参比化合物5-FU对Huh7细胞株具有更高的细胞毒性。然而,在所研究的条件下,所有化合物都没有表现出比5-FU对T47D细胞系更好的细胞毒活性。系列的代表性化合物,R2,在肝匀浆中以90、165和265 µM浓度抑制了线粒体呼吸,呈剂量依赖性,这表明线粒体呼吸可能是合成化合物细胞毒性的因素之一。可以选择化合物R2,R6和R7作为本研究的主要化合物,以进行进一步的研究。
  • Moriarty, Robert M.; Prakash, Om; Thachet, Cyriac T., Heterocycles, 1985, vol. 23, # 3, p. 633 - 639
    作者:Moriarty, Robert M.、Prakash, Om、Thachet, Cyriac T.、Musallam, Hikmat A.
    DOI:——
    日期:——
查看更多